Funding Opportunity RFA-AI-19-012 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support a national network of research centers for development of effective and comprehensive medical countermeasures applicable to all subsets of the civilian population in the event of radiological or nuclear emergencies. Applications are sought that propose multidisciplinary basic and translational research to support the development of new medical products that will assess, diagnose, mitigate and/or treat the short-, delayed- and long-term consequences of radiation exposure during and following a radiation public health emergency (e.g. a radiological/nuclear terrorist incident or accident). The goals of this FOA are to: 1) develop new techniques and devices to measure radiation exposure in the human body; 2) follow biomarkers of tissue damage and recovery; and 3) further develop existing (e.g. products in clinical use) as well as novel therapies to minimize tissue damage, hasten tissue recovery, restore normal physiological function, and improve survival.

Funding Opportunity RFA-ES-19-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Phase I (R43) and Fast-track (R44) Small Business Innovative Research (SBIR) grant applications from small business concerns (SBCs) in collaboration with environmental science researchers to develop novel tools, activities, or materials to build environmental health literacy for a variety of groups, including community members, health care and public health professionals, educators, and students of all ages.

Funding Opportunity RFA-ES-19-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Phase I (R43) and Fast-track (R44) Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) in collaboration with environmental science researchers to develop novel tools, activities, or materials to build environmental health literacy for a variety of groups, including community members, health care and public health professionals, educators, and students of all ages.

Notice NOT-FD-19-005 from the NIH Guide for Grants and Contracts

Notice NOT-DA-19-022 from the NIH Guide for Grants and Contracts

Prepares reports and documentation providing the analysis or summarization of project status and results. Knowledge of bioinformatics, experience designing...
From Exact Sciences Corporation - Fri, 08 Feb 2019 03:44:33 GMT - View all Madison, WI jobs

Notice NOT-AI-19-040 from the NIH Guide for Grants and Contracts

Notice NOT-AA-19-009 from the NIH Guide for Grants and Contracts

Notice NOT-HL-19-679 from the NIH Guide for Grants and Contracts

Notice NOT-FD-19-004 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-FD-19-010 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity is to support the research and development necessary to advance non-invasive (e.g., quantitative tomography-based) technologies, including the development of apparatus, methods, study designs, and methods of data analysis, to characterize and compare the rate and extent to which a topically applied drug becomes available at or near a site of action within the skin. The expectation is that the funded work will produce an accurate, sensitive and reproducible approach that rapidly measures the (relative) amount of drug present in the skin at a series of depths below the skin surface, which can be utilized to monitor the cutaneous pharmacokinetics (PK) of the drug at selected depths (e.g., in the epidermis and dermis) by repeated, serial measurements over time. The intent is to support the eventual development of an alternative, scientifically valid, cutaneous PK-based approach that can be used to efficiently demonstrate the bioequivalence (BE) of topical products.

Funding Opportunity RFA-FD-19-009 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity is to support research relevant to topical semisolid drug products that will help elucidate the relationship between a product's quality attributes and its functional properties. A specific purpose is to elucidate how characterizations of the arrangement of matter, including rheological characterizations (e.g., texture analysis, tribology) may correlate with and/or be predictive of sensorial differences perceived by human subjects (or patients). Upon the successful completion of this research, it should be possible to predict, based upon product quality characterizations, whether test and reference products that may be compositionally different are likely to have a comparable look and feel, including comparable perceptions of grittiness, silky-smoothness, and cooling sensation.

Funding Opportunity RFA-FD-19-008 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity is to support the research and development necessary to elucidate specific considerations that may be uniquely relevant to evaluating the bioequivalence (BE) of ungual (nail), scalp, vaginal, or rectal topical drug products. A specific emphasis of this funding opportunity involves the development of in vitro or ex vivo, comparative product characterization-based BE approaches.

Notice NOT-OD-19-072 from the NIH Guide for Grants and Contracts

Notice NOT-AI-19-035 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-19-022 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is aimed at discovering, determining the selectivity and sensitivity, and externally validating biological measures to be used for assessing, prognosing and monitoring recovery of youth who either clinically present with or are at risk for developing prolonged/persistent concussive symptoms following exposure to repetitive head impacts and/or concussion. Resultant biological measures should be incorporated into risk stratification algorithms to inform clinical care and patient stratification for future clinical trials. A critical feature of this FOA includes the broad sharing of clinical, neuroimaging, physiological, and biospecimen data to further advance research in the area of persistent concussive symptoms in children ages 9 - 14.

Notice NOT-AG-19-006 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-FD-19-014 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support research to develop and qualify a Patient Reported Outcome (PRO) for Non-Cystic Fibrosis Bronchiectasis (NCFB) under FDAs Drug Development Tools Qualification Program. This would include the qualitative phase of developing the instrument, quantitative phase of testing the instrument, and qualification of the instrument. It is expected that this qualified PRO would help improve upon the current design, conduct, and interpretation of anti-infective clinical trials in NCFB patients, for which optimal endpoints are currently lacking. This work directly aligns with FDAs research area of interest to stimulate innovation in clinical evaluations and personalized medicine to improve product performance and patient outcomes.

Funding Opportunity RFA-MH-20-110 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage research to integrate/harmonize existing data sets from preventive intervention trials implemented early in life to: 1) examine risk and protective factors relevant to later mental health outcomes in childhood, adolescence and young adulthood; and 2) determine whether preventive interventions delivered earlier in life have long-term effects, and/or cross-over effects (e.g., unanticipated beneficial effects), on important mental health outcomes, including serious mental illness (e.g., depression, anxiety, suicide ideation and behaviors, psychosis behaviors).

Competitive Salary: EMBL: EGA project coordinator Location: Cambridge, Cambridgeshire, England